First Tracks Biotherapeutics Inc (NASDAQ: TRAX) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
First Tracks Biotherapeutics Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $43.36, First Tracks Biotherapeutics Inc trades at 11.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -72.9%, return on invested capital of -107.6% and a free cash flow yield of -6.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 9.16. Over the past 52 weeks the share price ranged from $14.72 to $54.78, with a beta of 3.37.
First Tracks Biotherapeutics Inc does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.